Copyright © 2012 Dinesh Shetty et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. H. Li, X. Fan, and J. Houghton, “Tumor microenvironment: the role of the tumor stroma in cancer,” Journal of Cellular Biochemistry, vol. 101, no. 4, pp. 805–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
2. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8, pp. 858–864, 2004. View at Publisher · View at Google Scholar · View at Scopus
3. K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, and S. P. Colgan, “Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene,” Cancer Research, vol. 62, no. 12, pp. 3387–3394, 2002. View at Scopus
4. D. Feldser, F. Agani, N. V. Iyer, B. Pak, G. Ferreira, and G. L. Semenza, “Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2,” Cancer Research, vol. 59, no. 16, pp. 3915–3918, 1999. View at Scopus
5. H. Nishi, T. Nakada, S. Kyo, M. Inoue, J. W. Shay, and K. Isaka, “Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT),” Molecular and Cellular Biology, vol. 24, no. 13, pp. 6076–6083, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. R. Haubner, B. Kuhnast, C. Mang et al., “[${}^{18}\text{F}$]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates,” Bioconjugate Chemistry, vol. 15, no. 1, pp. 61–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
7. J. M. Jeong, M. K. Hong, Y. S. Chang et al., “Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice,” Journal of Nuclear Medicine, vol. 49, pp. 830–836, 2008.
8. M. Janssen, W. J. G. Oyen, L. F. A. G. Massuger et al., “Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting,” Cancer Biotherapy and Radiopharmaceuticals, vol. 17, no. 6, pp. 641–646, 2002. View at Scopus
9. G. B. Sivolapenko, D. Skarlos, D. Pectasides et al., “Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide,” European Journal of Nuclear Medicine, vol. 25, no. 10, pp. 1383–1389, 1998. View at Publisher · View at Google Scholar · View at Scopus
10. X. Chen, S. Liu, Y. Hou et al., “MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides,” Molecular Imaging and Biology, vol. 6, no. 5, pp. 350–359, 2004. View at Publisher · View at Google Scholar · View at Scopus
11. G. Thumshirn, U. Hersel, S. L. Goodman, and H. Kessler, “Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation,” Chemistry, vol. 9, no. 12, pp. 2717–2725, 2003. View at Publisher · View at Google Scholar · View at Scopus
12. L. Wang, J. Shi, Y. S. Kim et al., “Improving tumor-targeting capability and pharmacokinetics of ${}^{\text{99m}}\text{T}\text{c}$-Labeled cyclic RGD dimers with PEG4 linkers,” Molecular Pharmaceutics, vol. 6, no. 1, pp. 231–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
13. D. Sorger, M. Patt, P. Kumar et al., “[${}^{18}\text{F}$]Fluoroazomycinarabinofuranoside (${}^{18}\text{F}$AZA) and [${}^{18}\text{F}$]Fluoromisonidazole (${}^{18}\text{F}$MISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors,” Nuclear Medicine and Biology, vol. 30, no. 3, pp. 317–326, 2003. View at Publisher · View at Google Scholar · View at Scopus
14. T. Grönroos, O. Eskola, K. Lehtiö et al., “Pharmacokinetics of [${}^{18}\text{F}$]FETNIM: a potential hypoxia marker for PET,” Journal of Nuclear Medicine, vol. 42, no. 9, pp. 1397–1404, 2001. View at Scopus
15. M. B. Parliament, J. D. Chapman, R. C. Urtasun et al., “Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study,” British Journal of Cancer, vol. 65, no. 1, pp. 90–95, 1992. View at Scopus
16. S. T. Lee and A. M. Scott, “Hypoxia Positron Emission Tomography Imaging With ${}^{18}\text{F}$-Fluoromisonidazole,” Seminars in Nuclear Medicine, vol. 37, no. 6, pp. 451–461, 2007. View at Publisher · View at Google Scholar · View at Scopus
17. W. R. Dolbier Jr., A. R. Li, C. J. Koch, C. Y. Shiue, and A. V. Kachur, “[${}^{18}\text{F}$]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure,” Applied Radiation and Isotopes, vol. 54, no. 1, pp. 73–80, 2001. View at Publisher · View at Google Scholar · View at Scopus
18. Y. Fujibayashi, H. Taniuchi, Y. Yonekura, H. Ohtani, J. Konishi, and A. Yokoyama, “Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential,” Journal of Nuclear Medicine, vol. 38, pp. 1155–1160, 1997.
19. L. Hoigebazar, J. M. Jeong, S. Y. Choi et al., “Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice,” Journal of Medicinal Chemistry, vol. 53, no. 17, pp. 6378–6385, 2010. View at Publisher · View at Google Scholar · View at Scopus
20. L. Hoigebazar, J. M. Jeong, M. K. Hong et al., “Synthesis of 68Ga-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers,” Bioorganic and Medicinal Chemistry, vol. 19, no. 7, pp. 2176–2181, 2011. View at Publisher · View at Google Scholar · View at Scopus
21. T. A. Bonasera, G. Ortu, Y. Rozen et al., “Potential ${}^{18}\text{F}$-labeled biomarkers for epidermal growth factor receptor tyrosine kinase,” Nuclear Medicine and Biology, vol. 28, no. 4, pp. 359–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
22. A. Fredriksson, P. Johnstrom, J. O. Thorell et al., “In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants,” Life Sciences, vol. 65, pp. 165–174, 1999.
23. G. Ortu, I. Ben-David, Y. Rozen et al., “Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as pet biomarker for cancer and feasibility as anticancer drug,” International Journal of Cancer, vol. 101, no. 4, pp. 360–370, 2002. View at Publisher · View at Google Scholar · View at Scopus
24. G. Abourbeh, S. Dissoki, O. Jacobson et al., “Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors,” Nuclear Medicine and Biology, vol. 34, no. 1, pp. 55–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
25. S. Dissoki, D. Laky, and E. Mishani, “Fluorine-18 labeling of ML04—presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 49, no. 6, pp. 533–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
26. S. Nimmagadda, M. Pullambhatla, K. Stone, G. Green, Z. M. Bhujwalla, and M. G. Pomper, “Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography,” Cancer Research, vol. 70, no. 10, pp. 3935–3944, 2010. View at Publisher · View at Google Scholar · View at Scopus
27. R. A. de Silva, K. Peyre, M. Pullambhatla, J. J. Fox, M. G. Pomper, and S. Nimmagadda, “Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465,” Journal of Nuclear Medicine, vol. 52, pp. 986–993, 2011.
28. O. Jacobson, I. D. Weiss, D. O. Kiesewetter, J. M. Farber, and X. Chen, “PET of tumor CXCR4 expression with 4-${}^{18}\text{F}$-T140,” Journal of Nuclear Medicine, vol. 51, pp. 1796–1804, 2010.
29. O. Jacobson, I. D. Weiss, L. P. Szajek et al., “PET imaging of CXCR4 using copper-64 labeled peptide antagonist,” Theranostics, vol. 1, pp. 251–262, 2011.
30. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
31. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
32. C. R. Cooper, C. H. Chay, and K. J. Pienta, “The role of αvβ3 in prostate cancer progression,” Neoplasia, vol. 4, no. 3, pp. 191–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
33. J. D. Hood and D. A. Cheresh, “Role of integrins in cell invasion and migration,” Nature Reviews Cancer, vol. 2, no. 2, pp. 91–100, 2002. View at Scopus
34. O. Bögler and T. Mikkelsen, “Angiogenesis in glioma: molecular mechanisms and roadblocks to translation,” Cancer Journal, vol. 9, no. 3, pp. 205–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
35. P. C. Brooks, R. A. F. Clark, and D. A. Cheresh, “Requirement of vascular integrin α(v)β3 for angiogenesis,” Science, vol. 264, no. 5158, pp. 569–571, 1994. View at Scopus
36. J. Folkman, “Role of angiogenesis in tumor growth and metastasis,” Seminars in Oncology, vol. 29, no. 6, pp. 15–18, 2002. View at Scopus
37. M. Friedlander, P. C. Brooks, R. W. Shaffer, C. M. Kincaid, J. A. Varner, and D. A. Cheresh, “Definition of two angiogenic pathways by distinct αv integrins,” Science, vol. 270, no. 5241, pp. 1500–1502, 1995. View at Scopus
38. M. A. Horton, “The αvβ3 integrin 'vitronectin receptor',” International Journal of Biochemistry and Cell Biology, vol. 29, no. 5, pp. 721–725, 1997. View at Publisher · View at Google Scholar · View at Scopus
39. R. Hwang and J. Varner, “The role of integrins in tumor angiogenesis,” Hematology/Oncology Clinics of North America, vol. 18, no. 5, pp. 991–1006, 2004. View at Publisher · View at Google Scholar · View at Scopus
40. W. Cai, G. Niu, and X. Chen, “Imaging of integrins as biomarkers for tumor angiogenesis,” Current Pharmaceutical Design, vol. 14, no. 28, pp. 2943–2973, 2008. View at Publisher · View at Google Scholar · View at Scopus
41. W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen, “In vitro and in vivo characterization of 64Cu-labeled Abegrin™, a humanized monoclonal antibody against integrin αvβ3,” Cancer Research, vol. 66, no. 19, pp. 9673–9681, 2006. View at Publisher · View at Google Scholar · View at Scopus
42. R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
43. P. C. Brooks, A. M. P. Montgomery, M. Rosenfeld et al., “Integrin α(v)β3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels,” Cell, vol. 79, no. 7, pp. 1157–1164, 1994. View at Scopus
44. B. P. Eliceiri and D. A. Cheresh, “The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1227–1230, 1999. View at Scopus
45. S. Strömblad and D. A. Cheresh, “Integrins, angiogenesis and vascular cell survival,” Chemistry and Biology, vol. 3, no. 11, pp. 881–885, 1996. View at Scopus
46. Z. Liu, F. Wang, and X. Chen, “Integrin αvβ3-targeted cancer therapy,” Drug Development Research, vol. 69, no. 6, pp. 329–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
47. M. Aumailley, M. Gurrath, G. Muller, J. Calvete, R. Timpl, and H. Kessler, “Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1,” FEBS Letters, vol. 291, no. 1, pp. 50–54, 1991. View at Publisher · View at Google Scholar · View at Scopus
48. M. Gurrath, G. Muller, H. Kessler, M. Aumailley, and R. Timpl, “Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides,” European Journal of Biochemistry, vol. 210, no. 3, pp. 911–921, 1992. View at Publisher · View at Google Scholar · View at Scopus
49. R. Haubner, H. J. Wester, F. Burkhart et al., “Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics,” Journal of Nuclear Medicine, vol. 42, no. 2, pp. 326–336, 2001. View at Scopus
50. R. Haubner, H. J. Wester, U. Reuning et al., “Radiolabeled α(ν)β3 integrin antagonists: a new class of tracers for tumor targeting,” Journal of Nuclear Medicine, vol. 40, no. 6, pp. 1061–1071, 1999. View at Scopus
51. C. Henry, N. Moitessier, and Y. Chapleur, “Vitronectin receptor alpha(V)beta(3) integrin antagonists: chemical and structural requirements for activity and selectivity,” Mini Reviews in Medicinal Chemistry, vol. 2, no. 6, pp. 531–542, 2002. View at Scopus
52. J. S. Kerr, A. M. Slee, and S. A. Mousa, “Small molecule α(v) integrin antagonists: novel anticancer agents,” Expert Opinion on Investigational Drugs, vol. 9, no. 6, pp. 1271–1279, 2000. View at Scopus
53. M. Ogawa, K. Hatano, S. Oishi et al., “Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo αvβ3 integrin related tumor imaging,” Nuclear Medicine and Biology, vol. 30, no. 1, pp. 1–9, 2003. View at Publisher · View at Google Scholar · View at Scopus
54. Z. F. Su, G. Liu, S. Gupta, Z. Zhu, M. Rusckowski, and D. J. Hnatowich, “In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of αvβ3 integrin for tumor imaging,” Bioconjugate Chemistry, vol. 13, no. 3, pp. 561–570, 2002. View at Publisher · View at Google Scholar · View at Scopus
55. P. van Hagen, W. Breeman, H. Bernard et al., “Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy,” International Journal of Cancer, vol. 90, pp. 186–198, 2000.
56. A. J. Beer, A. L. Grosu, J. Carlsen et al., “[${}^{18}\text{F}$]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 13, pp. 6610–6616, 2007.
57. A. J. Beer, R. Haubner, M. Goebel et al., “Biodistribution and pharmacokinetics of the αvβ3-selective tracer ${}^{18}\text{F}$-Galacto-RGD in cancer patients,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1333–1341, 2005. View at Scopus
58. A. J. Beer, M. Niemeyer, J. Carlsen et al., “Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by ${}^{18}\text{F}$-Galacto-RGD PET,” Journal of Nuclear Medicine, vol. 49, pp. 255–259, 2008.
59. R. Haubner, W. A. Weber, A. J. Beer et al., “Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [${}^{18}\text{F}$] Galacto-RGD,” PLoS Medicine, vol. 2, p. e70, 2005. View at Publisher · View at Google Scholar · View at Scopus
60. L. M. Kenny, R. C. Coombes, I. Oulie et al., “Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand ${}^{18}\text{F}$-AH111585 in breast cancer patients,” Journal of Nuclear Medicine, vol. 49, pp. 879–886, 2008.
61. M. S. Morrison, S. A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge, “Use of a novel Arg-Gly-Asp radioligand, ${}^{18}\text{F}$-AH111585, to determine changes in tumor vascularity after antitumor therapy,” Journal of Nuclear Medicine, vol. 50, no. 1, pp. 116–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
62. R. Haubner, F. Bruchertseifer, M. Bock, H. Kessler, M. Schwaiger, and H. J. Wester, “Synthesis and biological evaluation of a ${}^{\text{99m}}\text{T}\text{c}$-labelled cyclic RGD peptide for imaging the αvβ3 expression,” NuklearMedizin, vol. 43, no. 1, pp. 26–32, 2004. View at Scopus
63. S. Liu, E. Cheung, M. C. Ziegler, M. Rajopadhye, and D. S. Edwards, “90Y and 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy,” Bioconjugate Chemistry, vol. 12, no. 4, pp. 559–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
64. S. Liu, D. S. Edwards, M. C. Ziegler, A. R. Harris, S. J. Hemingway, and J. A. Barrett, “${}^{\text{99m}}\text{T}\text{c}$-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors,” Bioconjugate Chemistry, vol. 12, no. 4, pp. 624–629, 2001. View at Publisher · View at Google Scholar · View at Scopus
65. X. Chen, M. Tohme, R. Park, Y. Hou, J. R. Bading, and P. S. Conti, “Micro-PET imaging of αvβ3-integrin expression with ${}^{18}\text{F}$-labeled dimeric RGD peptide,” Molecular Imaging, vol. 3, no. 2, pp. 96–104, 2004. View at Publisher · View at Google Scholar · View at Scopus
66. D. Boturyn, J. L. Coll, E. Garanger, M. C. Favrot, and P. Dumy, “Template Assembled Cyclopeptides as Multimeric System for Integrin Targeting and Endocytosis,” Journal of the American Chemical Society, vol. 126, no. 18, pp. 5730–5739, 2004. View at Publisher · View at Google Scholar · View at Scopus
67. T. Poethko, M. Schottelius, G. Thumshirn et al., “Two-step methodology for high-yield routine radiohalogenation of peptides: ${}^{18}\text{F}$-labeled RGD and octreotide analogs,” Journal of Nuclear Medicine, vol. 45, no. 5, pp. 892–902, 2004. View at Scopus
68. Z. B. Li, W. Cai, Q. Cao et al., “64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression,” Journal of Nuclear Medicine, vol. 48, no. 7, pp. 1162–1171, 2007. View at Publisher · View at Google Scholar · View at Scopus
69. Y. Wu, X. Zhang, Z. Xiong et al., “MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide,” Journal of Nuclear Medicine, vol. 46, pp. 1707–1718, 2005.
70. B. Jia, J. Shi, Z. Yang et al., “${}^{\text{99m}}\text{T}\text{c}$-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin αvβ3 expression,” Bioconjugate Chemistry, vol. 17, no. 4, pp. 1069–1076, 2006. View at Publisher · View at Google Scholar · View at Scopus
71. S. Liu, Y. S. Kim, W. Y. Hsieh, and S. Gupta Sreerama, “Coligand effects on the solution stability, biodistribution and metabolism of the ${}^{\text{99m}}\text{T}\text{c}$-labeled cyclic RGDfK tetramer,” Nuclear Medicine and Biology, vol. 35, no. 1, pp. 111–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
72. W. Cai, K. Chen, Z. B. Li, S. S. Gambhir, and X. Chen, “Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature,” Journal of Nuclear Medicine, vol. 48, pp. 1862–1870, 2007.
73. Z. Liu, W. Cai, L. He et al., “In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice,” Nature Nanotechnology, vol. 2, no. 1, pp. 47–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
74. X. Lin, J. Xie, G. Niu et al., “Chimeric ferritin nanocages for multiple function loading and multimodal imaging,” Nano Letters, vol. 11, no. 2, pp. 814–819, 2011. View at Publisher · View at Google Scholar · View at Scopus
75. R. H. Kimura, Z. Cheng, S. S. Gambhir, and J. R. Cochran, “Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects,” Cancer Research, vol. 69, no. 6, pp. 2435–2442, 2009. View at Publisher · View at Google Scholar · View at Scopus
76. R. H. Kimura, A. M. Levin, F. V. Cochran, and J. R. Cochran, “Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity,” Proteins: Structure, Function and Bioformatics, vol. 77, no. 2, pp. 359–369, 2009. View at Publisher · View at Google Scholar · View at Scopus
77. J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” Journal of Biomedical Optics, vol. 10, no. 5, Article ID 054010, 2005. View at Publisher · View at Google Scholar · View at Scopus
78. C. Li, W. Wang, Q. Wu et al., “Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe,” Nuclear Medicine and Biology, vol. 33, no. 3, pp. 349–358, 2006. View at Publisher · View at Google Scholar · View at Scopus
79. J. R. E. L. H. Helmut, O. M. Plotkina, U. P. C. S. R. Felixa, and H. Amthauera, “Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI,” Pancreatology, vol. 5, pp. 266–272, 2005.
80. H. K. Pannu, C. Cohade, R. E. Bristow, E. K. Fishman, and R. L. Wahl, “PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation,” Abdominal Imaging, vol. 29, no. 3, pp. 398–403, 2004. View at Scopus
81. H. Y. Lee, Z. Li, K. Chen et al., “PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles,” Journal of Nuclear Medicine, vol. 49, pp. 1371–1379, 2008.
82. M. Lijowski, S. Caruthers, G. Hu et al., “High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model,” Investigative Radiology, vol. 44, no. 1, pp. 15–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
83. N. Ferrara, K. Carver-Moore, H. Chen et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene,” Nature, vol. 380, no. 6573, pp. 439–442, 1996. View at Publisher · View at Google Scholar · View at Scopus
84. H. Akbulut, F. Altuntas, K. G. Akbulut et al., “Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma,” Cytokine, vol. 20, no. 4, pp. 184–190, 2002. View at Publisher · View at Google Scholar · View at Scopus
85. H. P. Gerber and N. Ferrara, “Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies,” Cancer Research, vol. 65, no. 3, pp. 671–680, 2005. View at Scopus
86. Y. Shimanuki, K. Takahashi, R. Cui et al., “Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer,” Lung, vol. 183, no. 1, pp. 29–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
87. L. Yen, X. L. You, A. E. Al Moustafa et al., “Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis,” Oncogene, vol. 19, no. 31, pp. 3460–3469, 2000. View at Scopus
88. E. K. Bergsland, “Update on clinical trials targeting vascular endothelial growth factor in cancer,” American Journal of Health-System Pharmacy, vol. 61, no. 21, pp. S12–S20, 2004. View at Scopus
89. N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Scopus
90. T. Shih and C. Lindley, “Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies,” Clinical Therapeutics, vol. 28, no. 11, pp. 1779–1802, 2006. View at Publisher · View at Google Scholar · View at Scopus
91. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
92. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” The New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
93. D. R. Collingridge, V. A. Carroll, M. Glaser et al., “The development of [124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography,” Cancer Research, vol. 62, no. 20, pp. 5912–5919, 2002. View at Scopus
94. G. C. Jayson, J. Zweit, A. Jackson et al., “Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1484–1493, 2002. View at Scopus
95. M. N. Lub-de Hooge, J. G. W. Kosterink, P. J. Perik et al., “Preclinical characterisation of 111In-DTPA-trastuzumab,” British Journal of Pharmacology, vol. 143, no. 1, pp. 99–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
96. P. J. Perik, M. N. Lub-de Hooge, J. A. Gietema et al., “Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 24, no. 15, pp. 2276–2282, 2006. View at Publisher · View at Google Scholar · View at Scopus
97. I. Verel, G. W. M. Visser, O. C. Boerman et al., “Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET,” Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 4, pp. 655–661, 2003. View at Scopus
98. W. Cai, K. Chen, K. A. Mohamedali et al., “PET of vascular endothelial growth factor receptor expression,” Journal of Nuclear Medicine, vol. 47, pp. 2048–2056, 2006.
99. W. B. Nagengast, E. G. de Vries, G. A. Hospers et al., “In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft,” Journal of Nuclear Medicine, vol. 48, no. 8, pp. 1313–1319, 2007. View at Publisher · View at Google Scholar · View at Scopus
100. M. G. W. Scheer, T. H. Stollman, O. C. Boerman et al., “Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression,” European Journal of Cancer, vol. 44, no. 13, pp. 1835–1840, 2008. View at Publisher · View at Google Scholar · View at Scopus
101. B. Paudyal, P. Paudyal, N. Oriuchi, H. Hanaoka, H. Tominaga, and K. Endo, “Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts,” Cancer Science, vol. 102, no. 1, pp. 117–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
102. D. E. Milenic, “Radioimmunotherapy: designer molecules to potentiate effective therapy,” Seminars in Radiation Oncology, vol. 10, no. 2, pp. 139–155, 2000. View at Scopus
103. A. Veeravagu, Z. Liu, G. Niu et al., “Integrin αvβ3-targeted radioimmunotherapy of glioblastoma multiforme,” Clinical Cancer Research, vol. 14, no. 22, pp. 7330–7339, 2008. View at Publisher · View at Google Scholar · View at Scopus
104. M. Janssen, C. Frielink, I. Dijkgraaf et al., “Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation,” Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 4, pp. 399–404, 2004. View at Publisher · View at Google Scholar · View at Scopus
105. Z. Liu, J. Shi, B. Jia et al., “Two 90Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy,” Molecular Pharmaceutics, vol. 8, no. 2, pp. 591–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
106. M. Yoshimoto, K. Ogawa, K. Washiyama et al., “αvβ3 integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide,” International Journal of Cancer, vol. 123, no. 3, pp. 709–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
107. L. Jiang, Z. Miao, R. H. Kimura et al., “Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 613–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
108. C. H. Ju, J. M. Jeong, Y. S. Lee et al., “Development of a 177Lu-labeled RGD derivative for targeting angiogenesis,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 6, pp. 687–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
109. T. D. Harris, S. Kalogeropoulos, T. Nguyen et al., “Design, synthesis, and evaluation of radiolabeled integrin α vβ3 receptor antagonists for tumor imaging and radiotherapy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 4, pp. 627–641, 2003. View at Scopus
110. R. P. Baum and F. Rösch, “1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23–26, 2011, Zentralklinik Bad Berka, Germany,” World Journal of Nuclear Medicine, vol. 10, p. 1, 2011.
111. S. Del Vecchio, A. Zannetti, R. Fonti, L. Pace, and M. Salvatore, “Nuclear imaging in cancer theranostics,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 51, p. 152, 2007.
112. O. Sowon, P. Vikas, and L. Dong Soo, “Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT,” International Journal of Molecular Imaging, vol. 2011, Article ID 524130, 7 pages, 2011. View at Publisher · View at Google Scholar
113. M. de Jong, W. H. Bakker, E. P. Krenning et al., “Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy,” European Journal of Nuclear Medicine, vol. 24, no. 4, pp. 368–371, 1997. View at Publisher · View at Google Scholar · View at Scopus
114. G. A. Kaltsas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
115. P. M. Smith-Jones, B. Stolz, R. Albert et al., “Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours,” Nuclear Medicine and Biology, vol. 25, no. 3, pp. 181–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
116. I. Massova, L. P. Kotra, R. Fridman, and S. Mobashery, “Matrix metalloproteinases: structures, evolution, and diversification,” The FASEB Journal, vol. 12, pp. 1075–1095, 1998.
117. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
118. J. H. McKerrow, V. Bhargava, E. Hansell et al., “A functional proteomics screen of proteases in colorectal carcinoma,” Molecular Medicine, vol. 6, pp. 450–460, 2000.
119. A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” Journal of Clinical Oncology, vol. 18, no. 5, pp. 1135–1149, 2000. View at Scopus
120. B. Davies, J. Waxman, H. Wasan et al., “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Research, vol. 53, no. 22, pp. 5365–5369, 1993. View at Scopus
121. J. R. MacDougall, M. R. Bani, Y. Lin, J. Rak, and R. S. Kerbel, “The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells,” Cancer Research, vol. 55, no. 18, pp. 4174–4181, 1995. View at Scopus
122. A. Vaisanen, H. Tuominen, M. Kallioinen, and T. Turpeenniemi-Hujanen, “Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value,” The Journal of Pathology, vol. 180, pp. 283–289, 1996.
123. Z. G. Zhou, X. J. Wu, L. R. Li et al., “A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients,” Chinese Medical Journal, vol. 124, no. 14, pp. 2132–2135, 2011. View at Publisher · View at Google Scholar · View at Scopus
124. P. D. Brown, “Clinical studies with matrix metalloproteinase inhibitors,” APMIS, vol. 107, no. 1, pp. 174–180, 1999. View at Scopus
125. Q. H. Zheng, X. Fei, X. Liu et al., “Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents,” Nuclear Medicine and Biology, vol. 29, no. 7, pp. 761–770, 2002. View at Publisher · View at Google Scholar · View at Scopus
126. X. Fei, Q. H. Zheng, X. Liu et al., “Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 13, pp. 2217–2222, 2003. View at Publisher · View at Google Scholar · View at Scopus
127. S. Furumoto, K. Takashima, K. Kubota, T. Ido, R. Iwata, and H. Fukuda, “Tumor detection using ${}^{18}\text{F}$-labeled matrix metalloproteinase-2 inhibitor,” Nuclear Medicine and Biology, vol. 30, no. 2, pp. 119–125, 2003. View at Publisher · View at Google Scholar · View at Scopus
128. K. Kopka, H. J. Breyholz, S. Wagner et al., “Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo,” Nuclear Medicine and Biology, vol. 31, no. 2, pp. 257–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
129. M. Schäfers, B. Riemann, K. Kopka et al., “Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo,” Circulation, vol. 109, no. 21, pp. 2554–2559, 2004. View at Publisher · View at Google Scholar · View at Scopus
130. R. Oltenfreiter, L. Staelens, V. Kersemans et al., “Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents,” Applied Radiation and Isotopes, vol. 64, no. 6, pp. 677–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
131. R. Oltenfreiter, L. Staelens, S. Labied et al., “Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 6, pp. 639–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
132. U. auf dem Keller, C. L. Bellac, Y. Li et al., “Novel matrix metalloproteinase inhibitor [${}^{18}\text{F}$]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer,” Cancer Research, vol. 70, no. 19, pp. 7562–7569, 2010. View at Publisher · View at Google Scholar · View at Scopus
133. N. Haider, D. Hartung, S. Fujimoto et al., “Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis,” Journal of Nuclear Cardiology, vol. 16, pp. 753–762, 2009.
134. S. Wagner, H. J. Breyholz, C. Holtke et al., “A new ${}^{18}\text{F}$-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies,” Applied Radiation and Isotopes, vol. 67, pp. 606–610, 2009.
135. R. Kulasegaram, B. Giersing, C. Page et al., “In vivo evaluation of 111 In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 28, pp. 756–761, 2001.
136. M. Ploug, “Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor,” Current Pharmaceutical Design, vol. 9, no. 19, pp. 1499–1528, 2003. View at Publisher · View at Google Scholar · View at Scopus
137. J. Rømer, B. S. Nielsen, and M. Ploug, “The urokinase receptor as a potential target in cancer therapy,” Current Pharmaceutical Design, vol. 10, no. 19, pp. 2359–2376, 2004. View at Publisher · View at Google Scholar · View at Scopus
138. J. A. Foekens, H. A. Peters, M.P. Look et al., “The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients,” Cancer Research, vol. 60, pp. 636–643, 2000.
139. F. Blasi and P. Carmeliet, “uPAR: a versatile signalling orchestrator,” Nature Reviews Molecular Cell Biology, vol. 3, no. 12, pp. 932–943, 2002. View at Publisher · View at Google Scholar · View at Scopus
140. Z. B. Li, G. Niu, H. Wang et al., “Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by micro PET,” Clinical Cancer Research, vol. 14, no. 15, pp. 4758–4766, 2008. View at Publisher · View at Google Scholar · View at Scopus
141. M. Ploug, S. Ostergaard, H. Gardsvoll et al., “Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation,” Biochemistry, vol. 40, pp. 12157–12168, 2001.
142. P. H. A. Quax, J. M. Grimbergen, M. Lansink et al., “Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 693–701, 1998. View at Scopus
143. S. Knör, S. Sato, T. Huber et al., “Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 53–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
144. D. Liu, D. Overbey, L. Watkinson, and M. F. Giblin, “Synthesis and characterization of an 111In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR),” Bioconjugate Chemistry, vol. 20, no. 5, pp. 888–894, 2009. View at Publisher · View at Google Scholar · View at Scopus
145. P. Vaupel and L. Harrison, “Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response,” Oncologist, vol. 9, no. 5, pp. 4–9, 2004. View at Scopus
146. J. R. Ballinger, “Imaging hypoxia in tumors,” Seminars in Nuclear Medicine, vol. 31, no. 4, pp. 321–329, 2001. View at Scopus
147. J. M. Brown, “The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain memorial award lecture,” Cancer Research, vol. 59, no. 23, pp. 5863–5870, 1999. View at Scopus
148. A. Nunn, K. Linder, and H. W. Strauss, “Nitroimidazoles and imaging hypoxia,” European Journal of Nuclear Medicine, vol. 22, no. 3, pp. 265–280, 1995. View at Publisher · View at Google Scholar · View at Scopus
149. W. L. Rumsey, B. Patel, and K. E. Linder, “Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart,” Journal of Nuclear Medicine, vol. 36, no. 4, pp. 632–636, 1995. View at Scopus
150. J. D. Chapman, A. J. Franko, and J. Sharplin, “A marker for hypoxic cells in tumours with potential clinical applicability,” British Journal of Cancer, vol. 43, no. 4, pp. 546–550, 1981. View at Scopus
151. E. J. Postema, A. J. B. McEwan, T. A. Riauka et al., “Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[ ${}^{18}\text{F}$]-fluoroarabinofuranosyl)-2-nitroimidazole (${}^{18}\text{F}$-FAZA),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 10, pp. 1565–1573, 2009. View at Publisher · View at Google Scholar · View at Scopus
152. A. L. Grosu, M. Souvatzoglou, B. Röper et al., “Hypoxia Imaging With FAZA-PET and Theoretical Considerations With Regard to Dose Painting for Individualization of Radiotherapy in Patients With Head and Neck Cancer,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 2, pp. 541–551, 2007. View at Publisher · View at Google Scholar · View at Scopus
153. G. Komar, M. Seppänen, O. Eskola et al., “${}^{18}\text{F}$-EF5: a new PET tracer for imaging hypoxia in head and neck cancer,” Journal of Nuclear Medicine, vol. 49, no. 12, pp. 1944–1951, 2008. View at Publisher · View at Google Scholar · View at Scopus
154. P. J. Blower, J. S. Lewis, and J. Zweit, “Copper radionuclides and radiopharmaceuticals in nuclear medicine,” Nuclear Medicine and Biology, vol. 23, no. 8, pp. 957–980, 1996. View at Publisher · View at Google Scholar · View at Scopus
155. T. Fukumura, K. Okada, H. Suzuki et al., “An improved 62Zn/62Cu generator based on a cation exchanger and its fully remote-controlled preparation for clinical use,” Nuclear Medicine and Biology, vol. 33, pp. 821–827, 2006.
156. N. G. Haynes, J. L. Lacy, N. Nayak et al., “Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM,” Journal of Nuclear Medicine, vol. 41, pp. 309–314, 2000.
157. D. W. McCarthy, L. A. Bass, P. D. Cutler et al., “High purity production and potential applications of copper-60 and copper-61,” Nuclear Medicine and Biology, vol. 26, no. 4, pp. 351–358, 1999. View at Publisher · View at Google Scholar · View at Scopus
158. D. W. McCarthy, R. E. Shefer, R. E. Klinkowstien et al., “Efficient production of high specific activity 64Cu using a biomedical cyclotron,” Nuclear Medicine and Biology, vol. 24, no. 1, pp. 35–43, 1997. View at Publisher · View at Google Scholar · View at Scopus
159. J. S. Rasey, W. J. Koh, M. L. Evans et al., “Quantifying regional hypoxia in human tumors with positron emission tomography of [${}^{18}\text{F}$]fluoromisonidazole: a pretherapy study of 37 patients,” International Journal of Radiation Oncology Biology Physics, vol. 36, no. 2, pp. 417–428, 1996. View at Publisher · View at Google Scholar · View at Scopus
160. J. S. Lewis, D. W. McCarthy, T. J. McCarthy, Y. Fujibayashi, and M. J. Welch, “Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model,” Journal of Nuclear Medicine, vol. 40, p. 177, 1999.
161. F. Dehdashti, P. W. Grigsby, J. S. Lewis, R. Laforest, B. A. Siegel, and M. J. Welch, “Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone),” Journal of Nuclear Medicine, vol. 49, pp. 201–205, 2008.
162. J. S. Lewis, R. Laforest, F. Dehdashti, P. W. Grigsby, M. J. Welch, and B. A. Siegel, “An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix,” Journal of Nuclear Medicine, vol. 49, no. 7, pp. 1177–1182, 2008. View at Publisher · View at Google Scholar · View at Scopus
163. P. Antunes, M. Ginj, H. Zhang et al., “Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 7, pp. 982–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
164. W. A. P. Breeman and A. M. Verbruggen, “The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 7, pp. 978–981, 2007. View at Publisher · View at Google Scholar · View at Scopus
165. M. A. Green and M. J. Welch, “Gallium radiopharmaceutical chemistry,” International Journal of Radiation Applications and Instrumentation B, vol. 16, pp. 435–448, 1989.
166. D. J. Hnatowich, “A review of radiopharmaceutical development with short lived generator produced radionuclides other than 99(m)Tc,” International Journal of Applied Radiation and Isotopes, vol. 28, no. 1-2, pp. 169–181, 1977. View at Publisher · View at Google Scholar · View at Scopus
167. D. Shetty, J. M. Jeong, C. H. Ju et al., “Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography,” Bioorganic and Medicinal Chemistry, vol. 18, no. 21, pp. 7338–7347, 2010. View at Publisher · View at Google Scholar · View at Scopus
168. D. Shetty, J. M. Jeong, C. H. Ju et al., “Synthesis of novel 68Ga-labeled amino acid derivatives for positron emission tomography of cancer cells,” Nuclear Medicine and Biology, vol. 37, no. 8, pp. 893–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
169. J. Baselga, “Targeting the epidermal growth factor receptor: a clinical reality,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 41S–44S, 2001. View at Scopus
170. E. Mishani, G. Abourbeh, O. Jacobson et al., “High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5337–5348, 2005. View at Publisher · View at Google Scholar · View at Scopus
171. A. Pal, A. Glekas, M. Doubrovin et al., “Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography,” Molecular Imaging and Biology, vol. 8, pp. 262–277, 2006.
172. J. Q. Wang, M. Gao, K. D. Miller, G. W. Sledge, and Q. H. Zheng, “Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 15, pp. 4102–4106, 2006. View at Publisher · View at Google Scholar · View at Scopus
173. Z. Levashova, M. V. Backer, G. Horng, D. Felsher, J. M. Backer, and F. G. Blankenberg, “SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF,” Bioconjugate Chemistry, vol. 20, no. 4, pp. 742–749, 2009. View at Publisher · View at Google Scholar · View at Scopus
174. M. V. Backer, Z. Levashova, V. Patel et al., “Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes,” Nature Medicine, vol. 13, no. 4, pp. 504–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
175. M. Hu, D. Scollard, C. Chan, P. Chen, K. Vallis, and R. M. Reilly, “Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF,” Nuclear Medicine and Biology, vol. 34, no. 8, pp. 887–896, 2007. View at Publisher · View at Google Scholar · View at Scopus
176. C. Neto, C. Fernandes, M. C. Oliveira et al., “Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents,” Nuclear Medicine and Biology, vol. 39, no. 2, pp. 247–260, 2012. View at Publisher · View at Google Scholar
177. J. Reubi, “Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy,” The Quarterly Journal of Nuclear Medicine, vol. 41, p. 63, 1997.
178. A. Schonbrunn, “Somatostatin receptors present knowledge and future directions,” Annals of Oncology, vol. 10, no. 2, pp. S17–S21, 1999. View at Scopus
179. J. C. Reubi, J. C. Schär, B. Waser et al., “Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 27, pp. 273–282, 2000.
180. D. J. Kwekkeboom, P. P. Kooij, W. H. Bakker, H. R. Mäcke, and E. P. Krenning, “Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake,” Journal of Nuclear Medicine, vol. 40, no. 5, pp. 762–767, 1999. View at Scopus
181. V. Rufini, M. L. Calcagni, and R. P. Baum, “Imaging of neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 36, no. 3, pp. 228–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
182. P. M. Smith-Jones, B. Stolz, C. Bruns et al., “Gallium-67/gallium-68-[DFO]-octreotide–a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies,” Journal of Nuclear Medicine, vol. 35, p. 317, 1994.
183. W. A. Breeman, M. de Jong, D. J. Kwekkeboom et al., “Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives,” European Journal of Nuclear Medicine, vol. 28, no. 9, pp. 1421–1429, 2001. View at Publisher · View at Google Scholar · View at Scopus
184. D. J. Kwekkeboom, J. Mueller-Brand, G. Paganelli et al., “Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs,” Journal of Nuclear Medicine, vol. 46, no. 1, p. 62S, 2005. View at Scopus
185. D. Wild, H. R. Mäcke, B. Waser et al., “68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 6, p. 724, 2005. View at Publisher · View at Google Scholar · View at Scopus
186. D. Wild, J. S. Schmitt, M. Ginj et al., “DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 10, pp. 1338–1347, 2003. View at Publisher · View at Google Scholar · View at Scopus
187. M. Fjalling, P. Andersson, E. Forssel Aronsson et al., “Systemic radionuclide therapy using indium-111-DTPA-D-Phe(1)-octreotide in midgut carcinoid syndrome,” Journal of Nuclear Medicine, vol. 37, pp. 1519–1521, 1996.
188. E. P. Krenning, M. de Jong, P. P. M. Kooij et al., “Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy,” Annals of Oncology, vol. 10, no. 2, pp. S23–S29, 1999. View at Scopus
189. G. Paganelli, S. Zoboli, M. Cremonesi et al., “Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide,” European Journal of Nuclear Medicine, vol. 28, no. 4, pp. 426–434, 2001. View at Publisher · View at Google Scholar · View at Scopus
190. R. Valkema, M. de Jong, W. H. Bakker et al., “Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam experience,” Seminars in Nuclear Medicine, vol. 32, no. 2, pp. 110–122, 2002. View at Scopus
191. M. de Jong, W. A. Breeman, B. F. Bernard et al., “[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy,” International Journal of Cancer, vol. 92, pp. 628–633, 2001.
192. L. Kolby, P. Bernhardt, V. Johanson et al., “Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour,” British Journal of Cancer, vol. 93, pp. 1144–1151, 2005.
193. V. Ambrosini, P. Tomassetti, P. Castellucci et al., “Comparison between 68Ga-DOTA-NOC and ${}^{18}\text{F}$-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 8, pp. 1431–1438, 2008. View at Publisher · View at Google Scholar · View at Scopus
194. I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and ${}^{18}\text{F}$-FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
195. D. J. Kwekkeboom, B. L. Kam, M. van Essen et al., “Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R53–R73, 2010. View at Publisher · View at Google Scholar · View at Scopus
196. H. R. Maecke and J. C. Reubi, “Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment,” Journal of Nuclear Medicine, vol. 52, no. 6, pp. 841–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
197. I. Virgolini, T. Traub, C. Novotny et al., “Experience with Indium-111 and Yttrium-90-labeled somatostatin analogs,” Current Pharmaceutical Design, vol. 8, no. 20, pp. 1781–1807, 2002. View at Publisher · View at Google Scholar · View at Scopus
198. R. P. Baum, V. Prasad, M. Hommann, and D. Hörsch, “Receptor PET/CT imaging of neuroendocrine tumors,” Recent Results in Cancer Research, vol. 170, pp. 225–242, 2008. View at Scopus
199. J. B. Cwikla, A. Sankowski, N. Seklecka et al., “Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study,” Annals of Oncology, vol. 21, no. 4, pp. 787–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
200. D. J. Kwekkeboom, W. H. Bakker, B. L. Kam et al., “Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 3, pp. 417–422, 2003. View at Scopus
201. D. J. Kwekkeboom, W. W. de Herder, B. L. Kam et al., “Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008. View at Publisher · View at Google Scholar · View at Scopus
202. J. Kunikowska, L. Królicki, A. Hubalewska-Dydejczyk, R. Mikołajczak, A. Sowa-Staszczak, and D. Pawlak, “Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 10, pp. 1788–1797, 2011. View at Publisher · View at Google Scholar · View at Scopus
203. R. Horuk, “Chemokine receptors,” Cytokine and Growth Factor Reviews, vol. 12, no. 4, pp. 313–335, 2001. View at Publisher · View at Google Scholar · View at Scopus
204. J. A. Burger and T. J. Kipps, “CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment,” Blood, vol. 107, no. 5, pp. 1761–1767, 2006. View at Publisher · View at Google Scholar · View at Scopus
205. K. E. Luker and G. D. Luker, “Functions of CXCL12 and CXCR4 in breast cancer,” Cancer Letters, vol. 238, no. 1, pp. 30–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
206. Y. Oda, H. Yamamoto, S. Tamiya et al., “CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis,” Modern Pathology, vol. 19, no. 5, pp. 738–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
207. O. Salvucci, A. Bouchard, A. Baccarelli et al., “The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study,” Breast Cancer Research and Treatment, vol. 97, no. 3, pp. 275–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
208. M. Darash-Yahana, E. Pikarsky, R. Abramovitch et al., “Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis,” The FASEB Journal, vol. 18, pp. 1240–1242, 2004.
209. D. Wong and W. Korz, “Translating an antagonist of chemokine receptor CXCR4: from bench to bedside,” Clinical Cancer Research, vol. 14, no. 24, pp. 7975–7980, 2008. View at Publisher · View at Google Scholar · View at Scopus
210. H. Hanaoka, T. Mukai, H. Tamamura et al., “Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors,” Nuclear Medicine and Biology, vol. 33, no. 4, pp. 489–494, 2006. View at Publisher · View at Google Scholar · View at Scopus
211. S. Nimmagadda, M. Pullambhatla, and M. G. Pomper, “Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT,” Journal of Nuclear Medicine, vol. 50, no. 7, pp. 1124–1130, 2009. View at Publisher · View at Google Scholar · View at Scopus
212. P. Misra, D. Lebeche, H. Ly et al., “Quantitation of CXCR4 expression in myocardial infarction using ${}^{\text{99m}}\text{T}\text{c}$-labeled SDF-1α,” Journal of Nuclear Medicine, vol. 49, no. 6, pp. 963–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
213. R. S. Y. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, and S. P. Fricker, “Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors,” Molecular Pharmacology, vol. 74, no. 6, pp. 1485–1495, 2008. View at Publisher · View at Google Scholar · View at Scopus
214. S. Hatse, K. Princen, E. de Clercq et al., “AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor,” Biochemical Pharmacology, vol. 70, no. 5, pp. 752–761, 2005. View at Publisher · View at Google Scholar · View at Scopus
215. E. Gourni, O. Demmer, M. Schottelius et al., “PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent,” Journal of Nuclear Medicine, vol. 52, pp. 1803–1810, 2011.